Javascript must be enabled to continue!
Percutaneous coronary intervention using drug‐eluting stents in pediatric heart transplant recipients
View through CrossRef
Abstract: PCI has been used for palliation of CAV in adults, but there are limited data available in children. We sought to evaluate our experience with PCIs for CAV in pediatric heart transplant recipients. Retrospective review of the medical records of all four patients who were diagnosed with CAV, including demographic data and catheterization reports was performed. Of the 149 pediatric heart transplant recipients followed at our institution, 10 were identified with CAV. Four of these 10 underwent 12 PCI procedures for CAV. One donor heart had documented coronary artery disease. Two patients had significant risk factors for coronary artery disease including morbid obesity, hyperlipidemia, and systemic hypertension. PCI involved deployment of bare metal stents (n = 2), paclitaxel‐eluting stent (n = 6), and sirolimus‐eluting stents (n = 4) with procedural success in all and no early or late mortality. One procedure was complicated by coronary dissection that was successfully treated with stent placement. One patient has been re‐transplanted while the other three are not candidates for re‐transplantation and have remained asymptomatic as palliation with PCI. PCI using coronary stents is a safe and effective palliative measure for CAV in pediatric heart transplant recipients.
Title: Percutaneous coronary intervention using drug‐eluting stents in pediatric heart transplant recipients
Description:
Abstract: PCI has been used for palliation of CAV in adults, but there are limited data available in children.
We sought to evaluate our experience with PCIs for CAV in pediatric heart transplant recipients.
Retrospective review of the medical records of all four patients who were diagnosed with CAV, including demographic data and catheterization reports was performed.
Of the 149 pediatric heart transplant recipients followed at our institution, 10 were identified with CAV.
Four of these 10 underwent 12 PCI procedures for CAV.
One donor heart had documented coronary artery disease.
Two patients had significant risk factors for coronary artery disease including morbid obesity, hyperlipidemia, and systemic hypertension.
PCI involved deployment of bare metal stents (n = 2), paclitaxel‐eluting stent (n = 6), and sirolimus‐eluting stents (n = 4) with procedural success in all and no early or late mortality.
One procedure was complicated by coronary dissection that was successfully treated with stent placement.
One patient has been re‐transplanted while the other three are not candidates for re‐transplantation and have remained asymptomatic as palliation with PCI.
PCI using coronary stents is a safe and effective palliative measure for CAV in pediatric heart transplant recipients.
Related Results
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract
Introduction
Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
BACKGROUND:
Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbrevi...
Predictors of insistent restenosis in patients undergoing percutaneous intervention
Predictors of insistent restenosis in patients undergoing percutaneous intervention
Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. The first percutaneous coronary intervention was performed by Andreas Gruntzig on Septemb...
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Two hundred forty-six patients with 252 bifurcation lesions were enrolled into a prospective, nonrandomized study to use paclitaxel-eluting or sirolimus-eluting stent for crush ste...
Drug-eluting stents: new era and new concerns
Drug-eluting stents: new era and new concerns
Abstract
At present there is much excitement about drug-eluting stents, which hold promise for the treatment of coronary artery disease. This ingenious therapy invol...
The use of drug eluting stents in single and multivessel disease: results from a single centre experience
The use of drug eluting stents in single and multivessel disease: results from a single centre experience
Objective: Drug eluting stents have been shown to reduce the rate of in-stent restenosis in cases where single lesions are treated. The performance of these stents, in patients wit...
GW24-e0529 Impact on endothelial repair after novel fully biodegradable drug-eluting scaffold implanted in porcine coronary model
GW24-e0529 Impact on endothelial repair after novel fully biodegradable drug-eluting scaffold implanted in porcine coronary model
Objectives
To observe the impact on endothelial repair of structure and function after novel fully biodegradable drug-eluting stent implanted in mini-pigs coronar...
Effects of PIP targeting LOX-1 eluting stents on in-stent restenosis and re-endothelialisation in rat abdominal aorta stenting models
Effects of PIP targeting LOX-1 eluting stents on in-stent restenosis and re-endothelialisation in rat abdominal aorta stenting models
Background and Objectives
Pyrrole-Imidazole polyamide (PIP) is a novel gene silencer that can be readily designed and synthesised to target any gene. Contrary to ...

